{"classes":[{"categories":[{"measurements":[{"comment":"Median PFS has not been reached due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"Progression free survival (PFS) was assessed based on time to disease progression or death (whichever occurred first) from the start of treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will be tested for Minimal Residual Disease (MRD) by Next Generation Sequencing (NGS) and flow cytometry after cycles 8 and 12. A treatment decision was made after cycle 12 based on these results. There are three outcomes based on the IFM trial (Avet-Loiseau et al., 2015): 1) if the subject is MRD-negative by NGS after cycle 8 and 12, the subject went on E-Rd maintenance until disease progression. 2) If the subject is MRD-positive after cycle 8 but MRD-negative after cycle 12, 6 more cycles of E-KRd was given and at the end of 18 cycles, the subject went on E-Rd maintenance until disease progression. 3) Finally, if the subject is MRD-positive at both instances, 12 additional cycles of E-KRd was given and at the end of 24 cycles total, the subject went on E-Rd maintenance until disease progression.\n\nElotuzumab: Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15\n\nCarfilzomib: Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond\n\nLenalidomide: Lenalidomide will be given on days 1-21 for all cycles.\n\nDexamethasone: Dexamethasone will be given as follows:\n\nCycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22","id":"OG000","title":"Elo-KRd Regimen"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to two years","title":"Median Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}